News
-
-
PRESS RELEASE
Zomedica Reports Record Revenue of $7.9 Million for the Fourth Quarter and $27.3 Million for the Full Year 2024; 70% Gross Margin, and $71 Million in Liquidity to Support Growth
Zomedica Corp. reports strong financial results for Q4 and FY 2024, with record revenue and growth in Diagnostics segment. Company's focus on accelerated revenue growth in 2025 highlighted -
-
-
-
PRESS RELEASE
Zomedica to Report Fourth Quarter and Full Year 2024 Financial Results with a Business Update on March 13th at 4:30 p.m. ET
Zomedica Corp. to host conference call on March 13, 2025, to discuss Q4 and FY 2024 financial results. Leading veterinary health company offering innovative solutions -
-
-
-
PRESS RELEASE
Zomedica Launches the TRUFORMA(R) Enhanced Endogenous ACTH Assay to aid in Equine PPID Diagnosis
Zomedica announces groundbreaking update to the TRUFORMA biosensor platform with enhancements to the eACTH assay for equine plasma, providing valuable insights into Pituitary Pars Intermedia Dysfunction (PPID) diagnosis